Guerbet S.A. (GUERF) Research

Guerbet S.A. focuses on pioneering and distributing contrast media, advanced delivery systems, medical devices, and associated technological solutions. Their product lineup features several iodinated contrast agents, including Optiray and Xenetix, which are non-ionic monomeric compounds, alongside Telebrix Gastro, a meglumine ioxitalamate solution, and Conray, an iothalamate meglumine injection. They also supply Micropaque/Microtrast for comprehensive diagnostic imaging. For Magnetic Resonance Imaging (MRI) applications, the company offers Dotarem, a gadoteric acid-gadoterate meglumine formulation, and Artirem, another gadoteric acid-based contrast agent. Complementing these are essential prefilled syringes, injectors, and various consumables designed for MRI, CT, and Cath Lab environments. The company also provides a suite of digital solutions, such as Contrast&Care for streamlined injection management, Dose&Care for precise X-ray dose monitoring, and icobrain, an AI-powered cloud platform that quantifies disease-specific brain structures from MR and CT scans to assist with acute and chronic neurological conditions. OptiProtect services are also available. In the realm of interventional radiology, Guerbet S.A. produces Lipiodol, comprising ethyl esters of iodinated fatty acids from poppyseed oil; Vectorio, a specialized mixing and injection system for conventional trans-arterial chemoembolization; Patent Blue V, a unique blue dye; Axessio, a peripheral micro guidewire; and microcatheters like SeQure and DraKon. Furthermore, they offer Hydra Vision, a digital imaging system tailored for urological, gastroenterological, and gynecological treatments, planning, and diagnostics, along with a range of urology accessories and consumables. Established in 1926, the company is headquartered in Villepinte, France.

Open Guerbet S.A. (GUERF) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.